Aromatase-deficient (ArKO) mice are retrieved from severe hepatic steatosis by peroxisome proliferator administration

Hepatology Research

Volumn 22, Issue 4, 2002, Pages 278-287

  Yoshikawa, Takashi ^a   Toda, Katsumi ^a   Nemoto, Yoshihisa ^a   Ono, Masafumi ^a   Iwasaki, Shinji ^a   Maeda, Takashi ^a   Saibara, Toshiji ^a   Hayashi, Yoshihiro ^a   Miyazaki, Eriko ^a   Hiroi, Makoto ^a   Enzan, Hideaki ^a   Shizuta, Yutaka ^a   Onishi, Saburo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Estrogen; Fatty liver; Mitochondria; Peroxisome proliferator; Peroxisome proliferator activated receptor

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ANTIESTROGEN; AROMATASE; BEZAFIBRATE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MESSENGER RNA; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME DEFICIENCY; ESTROGEN DEFICIENCY; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; IN VITRO STUDY; LIVER MICROSOME; LIVER MITOCHONDRION; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0036257387     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(01)00145-0     Document Type: Article

References (26)

1. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
2. Cirrhosis with steatohepatitis after adjuvant tamoxifen
3. Tamoxifen-induced steato-hepatitis
4. Tamoxifen-associated steatohepatitis-report of three cases
5. Tamoxifen-induced steatohepatitis
6. Tamoxifen-induced fatty liver in breast cancer patients
7. Bezafibrate for tamoxifen-induced non-alcoholic steato-hepatitis
8. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease
9. Non-alcoholic steatohepatitis: Another disease of affluence
10. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
11. Nonalcoholic steatohepatitis: A study of 49 patients
12. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
13. Altered constitutive expression of fatty acid-metabolizing enzymes in aromatase-deficient (ArKO) mice
14. Hepatic steatosis: Innocent bystander or guilty party?
15. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
16. Medical significance of peroxisome proliferator-activated receptors
17. Targeted disruption of the aromatase P450 gene (Cyp 19) in mice and their ovarian and uterine responses to 17beta-oestradiol
18. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice
19. Effects of administration of di-(2-ethylhexyl) phthalate on rat liver mitochondria
20. Abnormality of long-chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy
21. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis
22. The tissue-specific expression and developmental regulation of two nuclear genes encoding rat mitochondrial proteins: Medium-chain acyl-CoA dehydrogenase and mitochondrial malate dehydrogenase
23. Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenase and Q-subunit of electron transfer flavoprotein in rat
24. Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: A role for nuclear receptors in cardiac and brown adipose expression
25. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
26. On the mode of action of lipid-lowering agents; V. Kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase